HTFL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HeartFlow Inc (HTFL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promising revenue growth and a strong product pipeline, the recent price drop, insider selling, and lack of strong trading signals suggest waiting for a more favorable entry point.
The MACD is above 0 but contracting, indicating weakening momentum. RSI is neutral at 54.167, and moving averages are converging, showing no clear trend. Key support is at 24.79, with resistance at 28.063. The stock is currently trading near its pivot point, showing indecision.
HeartFlow reported a 40% YoY revenue increase for 2025 and projects further growth in
Capricorn Investment Group's acquisition of 1.66 million shares reflects confidence in the company's future.
Analysts maintain positive ratings, with price targets ranging from $35 to $43.
The stock experienced a significant regular market drop of -6.74%.
Insider selling by the CMO, reducing direct holdings by 72.8%.
The company continues to report net losses, with a net income of -$24.4 million in
Options data shows a high Open Interest Put-Call Ratio of 2.46, indicating bearish sentiment.
For Q4 2025, revenue increased to $49.13 million, gross margin improved to 79.51%, but the company reported a net loss of $24.4 million. EPS dropped to 0, reflecting ongoing profitability challenges.
Analysts maintain positive ratings with price targets between $35 and $43. Canaccord raised its target to $43, citing the Plaque Analysis launch momentum. JPMorgan lowered its target to $35 but remains optimistic about the company's growth prospects. Wells Fargo initiated coverage with an Overweight rating and a $38 target, highlighting the company's first-mover advantage in AI-based coronary artery disease diagnostics.
